CytomX Therapeutics (CTMX) Change in Account Payables (2014 - 2026)
CytomX Therapeutics (CTMX) reported Change in Account Payables of $67000.0 for Q1 2026, up 108.33% on a YoY basis from $32160.0 in Q1 2025, and down 89.77% quarter-over-quarter from $655000.0 in Q4 2025.
CytomX Therapeutics (CTMX) Change in Account Payables (2014 - 2026) Analysis & Trends
CytomX Therapeutics has reported Change in Account Payables for 13 years, with the latest figure at $67000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 108.33% year-over-year to $67000.0; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 164.92% YoY), and the FY2025 full-year result was $221000.0, up 174.41% from the prior year.
- Change in Account Payables for Q1 2026 stood at $67000.0, down from $655000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $3.3 million in Q3 2022, with the low at -$2.4 million in Q4 2022.
- Historically, Change in Account Payables has averaged -$80411.8 across 5 years, with a median of -$49000.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Account Payables surged 1875.68% — and 2023, when it plunged 635.19%.
- CytomX Therapeutics' Change in Account Payables stood at -$2.4 million in 2022, then soared by 86.18% to -$328000.0 in 2023, then climbed by 20.43% to -$261000.0 in 2024, then surged by 350.96% to $655000.0 in 2025, then sank by 89.77% to $67000.0 in 2026.
- The last three Change in Account Payables figures came in at $67000.0 (Q1 2026), $655000.0 (Q4 2025), and $419000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | CytomX Therapeutics | 520.30 Mn | 173.59 Mn | - | 67,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67,000.00 |
| Mar 31, 2026 | 67,000.00 |
| Dec 31, 2025 | 655,000.00 |
| Dec 31, 2025 | 655,000.00 |
| Sep 30, 2025 | 419,000.00 |
| Sep 30, 2025 | 419,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | -804,000.00 |
| Mar 31, 2025 | -804,000.00 |
| Dec 31, 2024 | -261,000.00 |
| Dec 31, 2024 | -261,000.00 |
| Sep 30, 2024 | 811,000.00 |
| Sep 30, 2024 | 811,000.00 |
| Jun 30, 2024 | -1.43 Mn |
| Jun 30, 2024 | -1.43 Mn |
| Mar 31, 2024 | 581,000.00 |
| Mar 31, 2024 | 581,000.00 |
| Dec 31, 2023 | -328,000.00 |
| Dec 31, 2023 | -328,000.00 |